Cassava Sciences Faces Fallout as Alzheimer's Drug Trial Fails
TL;DR
Cassava Sciences' Alzheimer's drug, simufilam, has failed in a large clinical trial, proving to be no more effective than a placebo. This outcome is particularly devastating for the nearly 2,000 participants involved, as the drug was based on falsified research and misleading claims. The failure highlights the ongoing challenges in Alzheimer's drug development and the significant time lost for those who participated in the trials.
- Cassava Sciences and its Alzheimer’s drug are done. The damage lingers STAT
- Cassava Sciences stock plummets after Phase III Alzheimer’s fail Yahoo Finance
- Cassava Sciences’ stock craters after Alzheimer’s disease trial fails MarketWatch
- Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops Investor's Business Daily
- Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints GlobeNewswire
Want the full story? Read the original reporting
Read on STAT